Contact Information
Department of Medicine
C/Villarroel, 136
adamo(a)ub.edu
Teaching imparted (current)
Màster en Biomedicina (Universitat de Barcelona): -
Biomedicina -
Universidad de Barcelona.
Curs Patologia Nutricional, Master Nutrició i malaties cróniques (Universitat de Barcelona) -
Innovació i Emprenedoria en Nutrició, Malalties Cròniques i Envelliment Saludable -
Universidad de Barcelona.
Oncologia Mèdica i Radioteràpica -
Medicina -
Universidad de Barcelona.
Master Universitario de Patología Mamaria-Senología -
Patologia Mamaria-Senologia -
Universidad de Barcelona.
Academic training
LLICENCIATURA EN MEDICINA
. Universitat de Messina. Messina, Itàlia.
. 2003
. (Diploma / Degree / Activities)PhD Program in Clinical Oncology
. Universitat de Messina
. 2011
. (Ph.D.)Especialització en Oncologia Mèdica
. Departament d'Oncologia Mèdica. Hospital Policlinico G. Martino, Universidad de Messina. Itàlia.
. 2007
. (Specialized Training)
Professional experience
Oncologia Mèdica a la Unitat de Fases 1.
Vall d'Hebron Institut d'Oncologia (VHIO). Hospital Universitari de la Vall d'Hebron.
09/2012 - 05/2014Oncologia Mèdica a la Unitat de Càncer de Mama.
Hospital Clínic de Barcelona.
05/2014Professora associada.
Universitat de Barcelona.
2019
Research Projects
Estudio de fase II, multicéntrico, aleatorizado, abierto, de tres grupos, de LAG525 administrado en combinación con spartallizumab (PDE001), o con
.
2019 - 2019
. Ref.2017-004865-28
. Novartis Farmacéutica, S.A
. PI: Barbara Adamo"A Phase 3, Open-Label, randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physicians's Choice in Germline BRCA
.
2019 - 2019
. Ref.HCB/16/644
. FUNDACIÓN GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER DE MAMA (GEICAM)
. PI: Barbara AdamoA phase II, Multi center study of BGB324 in combination with Pembrolizumab in patients with Previously treated, locally advanced and
.
2019 - 2019
. Ref.HCB/17/232
. INC Research UK Ltd.
. PI: Barbara AdamoLUCY - Lynparza Breast cancer real world utility, clinical effectiveness and safety study. A phase IIIb, single-arm, open-label multicentre study of
.
2019 - 2019
. Ref.HCB/17/704
. PAREXEL Global Operations Ireland
. PI: Barbara AdamoCaracterizacion de los linfocitos T CD8+/PD1+ en cancer de mama avanzado receptor hormonal-positivo con un fenotivo agresivo HER2-enriched
.
2019 - 2021
. Ref.19-IO-011
. Fundación Merck Salud
. PI: Aleix Prat Aparicio
Journal Publications
Martinez-Saez, Olga; Chic, Nuria; Pascual, Tomas; Adamo, Barbara; Vidal, Maria; Gonzalez-Farre, Blanca; Sanfeliu, Esther; Schettini, Francesco; Conte, Benedetta; Braso-Maristany, Fara; Rodriguez, Adela; Martinez, Debora; Galvan, Patricia; Rodriguez, Ana Belen; Martinez, Antonio; Munoz, Montserrat; Prat, Aleix(2020).
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.Breast Cancer Research, 22(1), p. 45
. Institutional Repository. ISSN: 1465-5411Adamo, Barbara; Bellet, Meritxell; Pare, Laia; Pascual, Tomas; Vidal, Maria; Perez Fidalgo, Jose A.; Blanch, Salvador; Martinez, Noelia; Murillo, Laura; Gomez-Pardo, Patricia; Lopez-Gonzalez, Ana; Amillano, Kepa; Canes, Jordi; Galvan, Patricia; Gonzalez-Farre, Blanca; Gonzalez, Xavier; Villagrasa, Patricia; Ciruelos, Eva; Prat, Aleix(2019).
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.Breast Cancer Research, 21(1)
. Institutional Repository. ISSN: 1465-5411Aleix Prat; Valentina Guarneri; Laia Paré; Gaia Griguolo; Tomás Pascual; Maria V Diec;, Núria Chic; Blanca González-Farré; Antonio Frassoldati; Esther Sanfeliu; Juan M Cejalvo; Montserrat Muñoz; Giancarlo Bisagni; Fara Brasó-Maristany; Loredana Urso; Maria Vidal; Alba A Brandes; Barbara Adamo; Antonino Musolino; Federica Miglietta; Benedetta Conte; Mafalda Oliveira; Cristina Saura; Sònia Pernas; Jesús Alarcón; Antonio Llombart-Cussac; Javier Cortés; Luis Manso; Rafael López; Eva Ciruelos; Francesco Schettini; Patricia Villagrasa; Lisa A Carey; Charles M Perou; Federico Piacentini; Roberto D'Amico: Enrico Tagliafico; Joel S Parker; Pierfranco Conte.(2020).
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.The Lancet Oncology, 21(11), pp. 1455 - 1464
. https://doi.org/10.1016/S1470-2045(20)30450-2. ISSN: 1470-2045Aleix Prat, Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, Maria Vidal, Fara Brasó-Maristany, Patricia Galván, Jan C. Brase, Vanessa Rodrik-Outmezguine, Stephen R.D. Johnston, Eva M Ciruelos and Joel S. Parker.(2020).
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer.Clinical Cancer Research
. https://doi.org/10.1158/1078-0432.CCR-20-2793. ISSN: 1078-0432Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF(2019).
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.JNCI: Journal of The National Cancer Institute
. https://doi.org/10.1093/jnci/djz042. ISSN: 0027-8874Adamo B; Rita Ricciardi GR; Ieni A; Franchina T; Fazzari C; Sanò MV; Angelico G; Michele C; Tuccari G; Adamo V.(2017).
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.Oncotarget, 8(44), pp. 76974 - 76986
. https://doi.org/10.18632/oncotarget.20293. ISSN: 1949-2553Adamo B; Ricciardi GRR; Ieni A; Franchina T; Fazzari C; Sanò MV; Angelico G; Caruso M; Tuccari G; Adamo V.(2019).
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.Oncotarget, 10(8), p. 917
. https://doi.org/10.18632/oncotarget.26650. ISSN: 1949-2553Prat A; Pascual T; Adamo B(2017).
Intrinsic molecular subtypes of HER2+ breast cancer.Oncotarget, 8(43), pp. 73362 - 73363
. https://doi.org/10.18632/oncotarget.20629. ISSN: 1949-2553Aleix Prat; Francesco Schettini; Nuria Chic; Fara Brasó-Maristany; Laia Paré Brunet; Tomás Pascual; Benedetta Conte; Olga Martínez-Sáez; Adamo B; Maria Vidal; Aranzazu Fernández-Martinez; Blanca González-Farre; Esther Sanfeliu; Juan Cejalvo; Giuseppe Perrone; Giovanna Sabarese; Francesca Zalfa; Patricia Villagrasa; Joaquín Gavilá; Carlos Barrios; Ana Lluch; Miguel Martin; Sabino De Placido; Esther Barnadas; Mariavittoria Locci; Vicente Peg; Roberta Fasani.(2021).
Clinical, pathological and PAM50 gene expression features of HER2-low breast cancer.npj Breast Cancer, 7
. Institutional Repository. ISSN: 2374-4677Pascual T; Fernandez-Martinez A; Tanioka M; Dieci MV; Pernas S; Gavilá J; Guarneri V; Cortés J; Villagrasa P; Chic N; Vidal M; Adamo B; Muñoz M; Griguolo G; Llombart-Cussac A; Conte P; Oliveira M; Conte B; Paré L; Galván P; Carey LA; Perou CM; Prat A;(2021).
Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy.Clinical Cancer Research
. https://doi.org/10.1158/1078-0432.CCR-20-4102. ISSN: 1078-0432
Other publications
M. Muñoz Mateu; B. Adamo; A. Arance Fernández;, J. M. Borràs André;, L. Gaba García; JJ Grau de Castro; J Maurel Santasusana; B Mellado González; A Prat Aparicio; N. Reguart Aransay; T. Saurí Nadal; A. Tuca Rodríguez; M. Vidal Losada; N Viñolas Segarra.(2020).
Sección VIII Oncología médica
. In
Medicina Interna
. Farreras-Rozman
. ISBN: 9788491135456
. https://bit.ly/39gzMT7